Dr. Philip M. Toleikis is Chief Technology Officer and Director of Sernova Corp. At Sernova, in his prior position as President and CEO held since 2009, Dr. Toleikis, has built international retail investor, banking and institutional relationships, securing over $100 million in various forms of financings, including equity raises, convertible debenture financing and multiple non-dilutive government grants. He is a pioneer in cell therapeutics and instrumental in developing Sernova’s disruptive technologies and corporate strategy to achieve potential ‘functional cures’ for chronic diseases such as diabetes, thyroid and rare diseases. He developed and expanded Sernova’s worldwide patent portfolio through patent prosecution and in licensing of key technologies and developed the Sernova team in advancement of the Cell Pouch System™ with successful GMP manufacturing, preclinical and clinical development in North America at the Univ. of Chicago.